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Background: Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor recep-
tor (EGFR)-mutated lung cancer. We hypothesized that the agent would have greater antitumor activity compared with
cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease
has progressed after platinum-containing therapy.
Patients and methods: An open-label, randomized, phase II trial was conducted in 43 centers; 124 patients were ran-
domized (1 : 1) to either afatinib (50 mg/day) or cetuximab (250 mg/m2/week) until disease progression or intolerable
adverse events (AEs) (stage I), with optional crossover (stage II). The primary end point was tumor shrinkage before cross-
over assessed by investigator (IR) and independent central review (ICR).
Results: A total of 121 patients were treated (61 afatinib, 60 cetuximab) and 68 crossed over to stage II (32 and 36 re-
spectively). In stage I, mean tumor shrinkage by IR/ICR was 10.4%/16.6% with afatinib and 5.4%/10.1% with cetuximab
(P = 0.46/0.30). Objective response rate was 16.1%/8.1% with afatinib and 6.5%/9.7% with cetuximab (IR/ICR).
Comparable disease control rates were observed with afatinib (50%) and cetuximab (56.5%) by IR; similar results were
seen by ICR. Most common grade ≥3 drug-related AEs (DRAEs) were rash/acne (18% versus 8.3%), diarrhea (14.8%
versus 0%), and stomatitis/mucositis (11.5% versus 0%) with afatinib and cetuximab, respectively. Patients with DRAEs
leading to treatment discontinuation were 23% with afatinib and 5% with cetuximab. In stage II, disease control rate
(IR/ICR) was 38.9%/33.3% with afatinib and 18.8%/18.8% with cetuximab.
Conclusion: Afatinib showed antitumor activity comparable to cetuximab in R/M HNSCC in this exploratory phase II
trial, although more patients on afatinib discontinued treatment due to AEs. Sequential EGFR/ErbB treatment with afatinib
and cetuximab provided sustained clinical benefit in patients after crossover, suggesting a lack of cross-resistance.
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introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer worldwide [1]. Patients diagnosed with
recurrent or metastatic (R/M) disease have a poor prognosis [2].
The majority of HNSCC tumors overexpress the epidermal
growth factor receptor (EGFR/ErbB1), which correlates with
poor clinical outcomes [3]; human epidermal growth factor
receptor 2 (HER2/ErbB2) amplification also occurs [4].
Cetuximab (EGFR monoclonal antibody) is indicated for loco-
regionally advanced and R/M HNSCC patients [5–7]. However,
the objective response (OR) to cetuximab monotherapy is
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modest (∼13%) [5], and predictive biomarkers of efficacy are
lacking. Somatic EGFR mutations in HNSCC are rare [4], and
while earlier reports documented EGFR deletion mutation
(EGFRvIII) in ∼40% of HNSCC tumors [8], more recently,
EGFRvIII mutations were only identified in <0.5% of 279
HNSCC samples from the Cancer Genome Atlas (TCGA)
project [4].
Afatinib, an oral, irreversible ErbB family blocker [9, 10] has
potent preclinical activity against wild-type and mutant EGFR
(including EGFRvIII) and HER2, and is used in the treatment of
patients with EGFR mutation-positive non-small-cell lung
cancer [9, 11, 12]. In HNSCC, EGFR tyrosine kinase inhibitor
therapy has been associated with low response rates [13–16] and
has not been directly compared with cetuximab. We hypothe-
sized that irreversible ErbB family blockade with afatinib would
have greater antitumor activity compared with cetuximab, and
that cross-resistance between them would not be universal, with
some patients potentially benefitting from sequential treatment.
patients andmethods
study design and patients
The study was conducted in 43 centers in Belgium, France, Spain and the
United States. Eligible patients (aged ≥18 years) had pathologically
confirmed R/M HNSCC, progression following any line of prior platinum-
based therapy, measurable disease [Response Evaluation Criteria In Solid
Tumors (RECIST) version 1.0], an Eastern Cooperative Oncology Group
performance status (ECOG PS) of ≤1, adequate end-organ function, and
provided written informed consent. Key exclusion criteria included: receiv-
ing more than two chemotherapeutic regimens for R/M disease and progres-
sive disease (PD) within 3 months of completion of intended curative
treatment of localized/locoregional advanced disease.
The study was conducted in accordance with the Declaration of Helsinki
and the International Conference on Harmonization Good Clinical Practice
guidelines, and approved by relevant regulatory and independent ethics
committees.
randomization and masking
Patients were randomized in a 1 : 1 ratio to afatinib or cetuximab in stage I,
stratified by number of prior chemotherapies for R/M HNSCC (0 versus
≥1). In stage I, patients received afatinib (50 mg once daily) or cetuximab
(loading dose of 400 mg/m2 followed by weekly doses of 250 mg/m2) treat-
ment until progression or intolerable adverse events (AEs). In stage II,
patients who failed or experienced intolerable AEs on afatinib or cetuximab
were able to cross over to the opposite treatment, cetuximab or afatinib (sup-
plementary Figure S1, available at Annals of Oncology online).
procedures
Patients experiencing grade ≥3 drug-related AEs (DRAEs) according to the
National Cancer Institute Common Terminology Criteria for AEs (NCI-
CTCAE) version 3.0 or grade ≥2 diarrhea, nausea, or vomiting for ≥7 con-
secutive days despite optimal supportive care, paused treatment (maximum
14 days). Following this and recovery to a grade ≤1 AE, afatinib was restarted
with the dose reduced by 10 mg; this reduction could be repeated twice.
Afatinib was discontinued after a third occurrence of AEs as specified above.
Patients who did not recover within 14 days could cross over to afatinib or
cetuximab in stage I, or be discontinued, if in stage II. Safety was assessed
every 2 weeks during the first cycle and then every 4 weeks.
end points and assessments
Primary end point was tumor shrinkage (mm) before crossover, defined as
the change from baseline in the smallest postrandomization sum of the
longest diameters (SLDs) of the target lesions. Secondary end points
included the best RECIST assessment, duration of OR, progression-free sur-
vival (PFS), overall survival (OS), safety, pharmacokinetic assessments (PK)
and patient-reported outcomes (PRO).
Computed tomography (CT) scans or magnetic resonance imaging
(MRI) were carried out at baseline and thereafter at 8-week intervals (stage
I). The last image before crossover was taken as baseline for stage II and
tumor assessments were carried out at weeks 4 and 8, and every 8 weeks fol-
lowing stage II treatment start. Tumor evaluation was conducted at investiga-
tional sites [investigator review (IR)] and by an independent central review
(ICR).
Blood samples for PK analyses were collected from all patients who
received afatinib in stage I and patients who crossed over from cetuximab to
afatinib treatment in stage II. Plasma concentrations of afatinib were analyzed
by a validated high-performance liquid chromatography tandem mass spec-
trometry method using [D6]afatinib as an internal standard.
PRO were assessed using the self-administered European Organization
for Research and Treatment of Cancer-Quality of Life Questionnaire
(EORTC QLQ)-C30 and its head and neck-specific module (QLQ-HN35)
[17, 18]. Prespecified assessments included time to deterioration in global
health status as well as head and neck-specific symptoms of pain and swal-
lowing.
Immunohistochemistry (IHC) established p16 expression and EGFRvIII
mutation status; the latter was also determined using quantitative reverse
transcription polymerase chain reaction as previously described [19].
statistical analysis
Tumor shrinkage based on the continuous variable, SLD of target lesions,
was chosen because it was expected to be more sensitive in detecting differ-
ences between treatment groups, compared with a binary variable, such as
response rate [20]. In determining sample size, 40 patients per treatment
group with at least one postrandomization tumor assessment were expected
to provide ∼80% power to detect a difference of 0.38 standard deviation in
the true mean tumor shrinkage between groups, using a one-sided α level of
0.20. This could provide ∼80% power to detect a difference of 18% in the
objective response rate (ORR).
Comparisons between afatinib and cetuximab were made via analysis of
covariance for tumor shrinkage, Cochran’s statistics for best RECIST assess-
ment, log-rank test and Cox proportional hazards regression for PFS and
OS. PRO analysis focused on time to deterioration (defined as a 10-point
change towards worsening from baseline score on a 0–100 point scale) for:
global health status (Q29 and Q30 in C30), pain (Q9 and Q19 in C30) and
swallowing (Q35 to Q38 in H&N35). Safety end points were analyzed
descriptively.
For stage I, efficacy analyses included all randomized patients, and safety
analyses comprised the treated population. Efficacy and safety analyses in
stage II included all treated patients.
results
patient population
Between October 2007 and June 2011, 124 patients were rando-
mized to receive afatinib (62 patients) or cetuximab (62 patients)
during stage I (Figure 1). Baseline characteristics were balanced
(Table 1); although, there were more patients with ECOG PS 0
in the afatinib group [23 (37.1%)] versus cetuximab [11
(17.7%)].
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tumor shrinkage
stage I. Comparable tumor reduction was observed in both
afatinib and cetuximab groups (P = 0.57 per ICR and 0.76 per
IR, Figure 2A and B). Per ICR, 16 of 47 (34%) afatinib-treated
patients experienced tumor size reduction of >30% versus 9 of
48 (18.7%) on cetuximab (Figure 3).
stage II. Overall, 12/30 (40%) of afatinib- and 8/26 (30.8%) of
cetuximab-treated assessable patients had a reduction in SLD by
ICR (Figure 3). Waterfall plots show that one patient in each
group experienced tumor size reduction of >30%.
RECIST-defined response. During stage I, confirmed ORR was
16.1% with afatinib and 6.5% with cetuximab (P = 0.09) by IR
and 8.1% with afatinib and 9.7% with cetuximab (P = 0.78) by
ICR (supplementary Table S1, available at Annals of Oncology
online). There was disparity in agreement between IR and ICR,
and in particular between reviewers within the ICR, where 49
of 106 cases (46%) required third-reader arbitration due to
discrepancies between the first two readers. Disease control was
achieved in 31 (50%) afatinib- and 35 (56.5%) cetuximab-
treated patients by IR (P = 0.48) with similar findings using ICR
in stage I (supplementary Table S1, available at Annals of
Oncology online). ORRs in both groups were similar per ICR,
regardless of prior chemotherapy in the R/M setting; per IR,
afatinib showed higher ORR in patients with prior chemotherapy
in the R/M setting (supplementary Table S2, available at Annals
of Oncology online).
During stage II, the disease control rate (IR/ICR) for patients
who switched from cetuximab to afatinib was 38.9%/33.3%
compared with 18.8%/18.8% for those switched from afatinib to
cetuximab (supplementary Table S1, available at Annals of
Oncology online). Interestingly, several patients on both treat-
ments appeared to maintain disease control after crossover
(Figure 4).
PFS and OS. In stage I, median PFS by ICR for afatinib- and
cetuximab-treated patients was similar; 13.0 versus 15.0 weeks
[hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.62–1.38,
P = 0.71, supplementary Figure S2A, available at Annals of
Oncology online]. For stage II, median PFS for patients who
crossed over to afatinib was 9.3 and 5.7 weeks for those crossing to
cetuximab (HR 0.64, 95% CI 0.38–1.05, P = 0.08, supplementary
Figure S2B, available at Annals of Oncology online).
Median OS was 35.9 weeks for afatinib- and 47.1 weeks for
cetuximab-treated patients during stage I and II (HR 1.06, 95%
Stage I
Stage II
62 assigned to afatinib
   1 did not receive afatinib
     61 received afatinib
32 crossed to stage II
       5 due to AEs
       4 due to clinical progression
     14 due to radiological progression
       9 due to clinical and radiological progression
32 discontinued stage II
     27 due to progressive disease
       3 due to AEs
       2 refused to continue treatment
36 discontinued stage II
     24 due to progressive disease
     10 due to AEs
       2 other reason
36 crossed to stage II
       3 due to AEs
       6 due to clinical progression
     13 due to radiological progression
     14 due to clinical and radiological progression
29 discontinued stage I
  4 due to progressive disease
  8 refused to continue treatment
  1 other reason
23 discontinued stage I
     8 due to progressive disease
     5 due to AEs
     3 refused to continue treatment
     7 other reason
62 assigned to cetuximab
   2 did not receive cetuximab
     60 received cetuximab
146 assessed for eligibility
124 randomly allocated to treatment
32 received cetuximab in stage II 36 received afatinib in stage II
22 excluded: screening failures
16 due to AEs
1 still receiving
cetuximab in stage I
(06 June 2013)
Figure 1. Participant flow diagram. AE, adverse event.
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CI 0.70–1.62, P = 0.78, supplementary Figure S3, available at
Annals of Oncology online).
patient-reported outcomes. During both stages, PRO outcomes
were comparable in both treatment groups for global health
status, pain and swallowing (supplementary Figure S4, available
at Annals of Oncology online).
PK assessments. Afatinib plasma levels reached steady state by
day 15 and trough plasma concentrations were generally stable
over the observation period (56 days), with no apparent
differences between stages I and II (supplementary Figure S5A,
available at Annals of Oncology online). Afatinib plasma
concentrations were similar across different administration
routes (oral tablet, gastric feeding tube and dispersion)
(supplementary Figure S5B, available at Annals of Oncology
online).
EGFRvIII and p16 analysis. None of the 53 patients (25
afatinib, 28 cetuximab) with tumor samples for EGFRvIII
mutation analysis harbored the EGFRvIII mutation. Of 65
patients (34 afatinib, 31 cetuximab) with samples for p16
analysis, 48 (74%) tested negative for p16 (25 afatinib, 23
cetuximab). Two responses were observed in p16-positive
patients by ICR, one in each treatment group (supplementary
Table S2, available at Annals of Oncology online).
AEs, dose reductions and treatment discontinuation. During
stage I, 59/61 afatinib- and 51/60 cetuximab-treated patients
had a DRAE, of which rash/acne and diarrhea were most
common (Table 2). DRAEs led to dose reduction in 18 [29.5%;
9 (14.8%) rash/acne, 5 (8.2%) diarrhea, 3 (4.9%) mucosal
inflammation and 1 (1.6%) fatigue] afatinib- and two (3.3%; one
rash and one rash/skin fissures) cetuximab-treated patients.
Discontinuation due to DRAEs occurred in 14 (23%) and 3
(5%) afatinib- and cetuximab-treated patients. Serious AEs that
Table 1. Demographics, baseline disease characteristics
and treatment history for randomized patients
Afatinib
(N = 62)
Cetuximab
(N = 62)
Gender, n (%)
Female 7 (11.3) 10 (16.1)
Male 55 (88.7) 52 (83.9)
Race, n (%)
Black 1 (1.6) 4 (6.5)
White 45 (72.6) 41 (66.1)
American Indian/Alaska
Natives
1 (1.6) 0
Missing 15 (24.2) 17 (27.4)
Age (years)
Median (range) 58.0 (23–78) 58.0 (29–83)
Weight (kg)
Median (range) 70.0 (43–114) 61.3 (37–109)
ECOG performance status
0 23 (37.1) 11 (17.7)
1 38 (61.3) 48 (77.4)
2a 0 1 (1.6)
Missing 1 (2.6) 2 (3.2)
Primary tumor site, n (%)
Oral cavity 13 (21.0) 16 (25.8)
Oropharynx 22 (35.5) 16 (25.8)
Hypopharynx 10 (16.1) 9 (14.5)
Larynx 8 (12.9) 12 (19.4)
Nasopharynx 1 (1.6) 0
Pharynx 1 (1.6) 1 (1.6)
Sinus 3 (4.8) 2 (3.2)
Unknown primary 3 (4.8) 6 (9.7)
Missing 1 (1.6) 0
Clinical stage at diagnosis, n (%)
I 3 (4.8) 4 (6.5)
II 3 (4.8) 6 (9.7)
III 9 (14.5) 15 (24.2)
IVa 28 (45.2) 23 (37.1)
IVb 10 (16.1) 12 (19.4)
IVc 8 (12.9) 2 (3.2)
Missing 1 (1.6) 0
Metastasis and recurrence
Local only 17 (27.4) 19 (30.6)
Distant only 19 (30.6) 18 (29.0)
Both 24 (38.7) 24 (38.7)
Missing 2 (3.2) 1 (1.6)
Number of prior chemotherapies,b n (%)
1 28 (45.2) 33 (53.2)
2 29 (46.8) 22 (35.5)
3 3 (4.8) 5 (8.1)
4 1 (1.6) 2 (3.2)
Missing 1 (1.6) 0
Prior chemotherapy for R/M disease, n (%)
Yes 42 (67.7) 41 (66.1)
No 20 (32.3) 21 (33.9)
Other prior anticancer therapies, n (%)
Surgery 48 (77.4) 45 (72.6)
Radiotherapy 56 (90.3) 60 (96.8)
Missing 1 (1.6) 0
Continued
Table 1. Continued
Afatinib
(N = 62)
Cetuximab
(N = 62)
EGFRvIII mutation status, n (%)
Positive 0 0
Negative 25 (40.3) 28 (45.2)
Unknown 37 (59.7) 34 (54.8)
p16 status, n (%)
Positive 9 (14.5) 8 (12.9)
Negative 25 (40.3) 23 (37.1)
Unknown 28 (45.2) 31 (50.0)
aPatient with ECOG performance status 2 was recorded as a protocol
violation.
bAny chemotherapy received since diagnosis. Note: Percentage
calculated from the total population; some factors total <100% due
to missing data.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal
growth factor receptor.
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were possibly treatment-related occurred in 19 (31.1%) and 2
(3.3%) of afatinib- and cetuximab-treated patients, of which one
was fatal (grade 5 pyrexia in the afatinib group). Similar AEs
were reported during stages I and II; grade ≥3 rash/acne,
diarrhea and dry skin occurred most often in stage II (Table 2).
discussion
This is the only reported randomized trial to compare an irre-
versible, small molecule ErbB family blocker with cetuximab in
patients with R/M HNSCC who progressed after platinum-based
chemotherapy and investigate dual sequential treatment with
these ErbB family-targeting agents. Afatinib showed comparable
activity to cetuximab and the sequential treatment appeared to
sustain clinical benefit, demonstrating a lack of cross-resistance
between the two agents. In addition, afatinib levels were similar
across different administration routes, suggesting that optimal
doses of afatinib can be achieved in tube-feeding patients.
The primary outcome measure of tumor shrinkage as a continu-
ous variable (assessed using RECIST) was chosen as it provides
distinct power advantages compared with otherwise identical
trial designs that use categorical outcomes [21]. Continuous
outcome measures can enable smaller, more efficient rando-
mized trials and randomized trials are generally more inform-
ative than single-arm studies with historical controls. Here,
tumor shrinkage and response rate results were exactly concord-
ant and demonstrate that the study design using the continuous
outcome variable did not influence findings.
Evidence of disease control was visible in both crossover treat-
ment arms with sequential EGFR/ErbB-targeting therapy using
cetuximab followed by afatinib or vice versa. This finding may
be clinically meaningful, especially as few approved therapies
and no targeted agents are available in this treatment setting
and non-cross-resistance with any other commonly used agents
is likely (e.g. cytotoxic chemotherapy). This is the first report in
HNSCC where PD under treatment with an EGFR-targeting
monoclonal antibody does not necessarily induce resistance to a
subsequent small molecule ErbB-targeted agent. However, it is
unclear what precise mechanism of action of afatinib this relates
to and further mechanistic insights and biomarker discovery are
required to decipher this. It is interesting to note that HER2 is
altered in 3%–5% of HNSCC tumors as recently reported by
TCGA and this could be a potential mechanism by which afati-
nib acts after failure [4].
We were unable to identify EGFRvIII mutations in 53
samples tested, and taken together with a report of head and
neck cancer exome sequencing that also could not identify
EGFRvIII mutations at the DNA level in 74 samples [22], there
is no clear evidence that EGFRvIII is present at a meaningful
frequency in HNSCC populations [4]. While preclinical data
showed that afatinib potently inhibits EGFRvIII(+) cells, this is
unlikely to be the underlying mechanism of action in HNSCC
or differential activity compared with cetuximab.
Frequency of grade ≥3 DRAEs was greater with afatinib than
cetuximab, with grade ≥3 diarrhea and rash accounting for
more dose reductions and discontinuations in the afatinib
group, although this did not translate into efficacy differences.
Despite the greater proportion of DRAEs observed with afatinib,
significant deterioration in PRO end points was not noted com-
pared with cetuximab. Proactive management of AEs associated
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Figure 2. (A) Primary end point: mean tumor shrinkagea after treatment (stage I); (B) mean percentage changeb in tumor shrinkage (stage I). aTumor shrink-
age was defined as the change from baseline in the smallest postrandomization sum of the longest diameters of the target lesions; adjusted mean change. Only
patients with baseline and at least one postrandomization measurement are included in these analyses. Independent central review, n = 48 for afatinib and
n = 48 for cetuximab; investigator review, n = 50 for afatinib and n = 55 for cetuximab. bAdjusted mean change. Only patients with baseline and at least one
postrandomization measurement are included in these analyses. Independent central review, n = 47 for afatinib and n = 48 for cetuximab; investigator review,
n = 50 for afatinib and n = 55 for cetuximab.
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with EGFR-targeted therapies is essential and frequently suc-
cessful in allowing patients to continue treatment [23, 24]. Of
note, more recent studies with afatinib, including phase III
trials in HNSCC, recommend a starting dose of 40 mg (instead
of 50 mg) based on safety evaluations (e.g. NCT01345682,
NCT01345669 and NCT01856478).
Our data suggest that afatinib has comparable activity to
cetuximab in R/M HNSCC. Evidence of a lack of cross-resistance
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have a baseline and postbaseline measurement for inclusion in the assessment of the tumor shrinkage (and Response Evaluation Criteria In Solid Tumors
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between these agents demonstrated by sustained clinical benefit
of sequential EGFR/ErbB family therapy in a subgroup of
patients is novel and potentially clinically meaningful, especially
if biomarkers could be used to select patients.
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cetuximab (again, differentiated by color) according to investigator review.
Table 2. Treatment-related AEs in stages I and II for all grades and CTCAE grades 3–4 in ≥10% of patients in either treatment group
CTCAE grades Stage I Stage II
Afatinib (N = 61) Cetuximab (N = 60) Cetuximab→ afatinib
(N = 36)
Afatinib→ cetuximab
(N = 32)
All 3–4 All 3–4 All 3–4 All 3–4
Total, n (%) 59 (96.7) 32 (52.5) 51 (85.0) 11 (18.4) 31 (86.1) 17 (47.2) 22 (68.8) 5 (15.6)
Rash/acnea 48 (78.7) 11 (18.0) 46 (76.7) 5 (8.3) 20 (55.6) 9 (25.0) 14 (43.8) 4 (12.5)
Diarrhea 48 (78.7) 9 (14.8) 12 (20.0) 0 19 (52.8) 4 (11.1) 1 (3.1) 0
Stomatitisa,b 21 (34.4) 7 (11.5) 14 (23.3) 0 8 (22.2) 1 (2.8) 2 (6.3) 0
Fatiguea 20 (32.8) 3 (4.9) 13 (21.7) 1 (1.7) 4 (11.1) 1 (2.8) 2 (6.3) 0
Nausea 17 (27.9) 1 (1.6) 12 (20.0) 1 (1.7) 5 (13.9) 0 1 (3.1) 0
Vomiting 10 (16.4) 1 (1.6) 8 (13.3) 0 3 (8.3) 0 1 (3.1) 0
Dry skin 9 (14.8) 0 15 (25.0) 0 4 (11.1) 2 (5.6) 3 (9.4) 1 (3.1)
Dehydration 8 (13.1) 5 (8.2) 1 (1.7) 0 0 0 0 0
Decreased appetite 5 (8.2) 3 (4.9) 8 (13.3) 0 6 (16.7) 1 (2.8) 2 (6.3) 0
Nail effectsa,c 4 (6.6) 0 6 (10.0) 1 (1.7) 2 (5.6) 0 3 (9.4) 0
Ocular effectsa,d 4 (6.6) 0 6 (10.0) 1 (1.7) 5 (13.9) 1 (2.8) 0 0
Constipation 2 (3.3) 0 7 (11.7) 0 0 0 1 (3.1) 0
aGrouped terms of closely related AEs. Table sorted by afatinib ‘all grades’ in stage I.
bDuring stage I, the most frequently reported treatment-related AE within the grouped term ‘stomatitis’ was mucosal inflammation (afatinib 21.3%
and cetuximab 13.3%).
cDuring stage I, the most frequently reported AE within the grouped term ‘nail effects’ was paronychia (afatinib 4.9% and cetuximab 6.7%).
dDuring stage I, the most frequently reported AEs within the grouped term ‘ocular effects’ were conjunctivitis (afatinib 3.3% and cetuximab 8.3%)
and periorbital edema (afatinib 3.3% and cetuximab 0%).
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events.
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